{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-000270","form_type":"8-K","ticker":"GNLX","cik":"0001231457","company_name":"GENELUX Corp","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.668045+00:00","generated_at":"2026-05-16T11:38:21.360425+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec","bullets":["SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.","NSCLC Phase 2 VIRO-25: 60% DCR (3/5 patients); tumor size changes -18.9% and -22.7% in two of three DCR patients.","Durability signals: two SCLC PR patients had PFS of 12.1 mo (1 prior line) and 7.7 mo (4 prior lines).","Topline Phase 3 ovarian cancer data expected H2 2026; additional lung cancer interim readouts throughout 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-000270","json":"https://secwatch.observer/filing/0001493152-26-000270.json","markdown":"https://secwatch.observer/filing/0001493152-26-000270.md","text":"https://secwatch.observer/filing/0001493152-26-000270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/0001493152-26-000270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:38:21.360425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}